KLRB1 and cancer: CD161 phenotyping showed that 3 of 6 of donors had cancer-reactive T cells expressing CD161, with levels less than that of a MAIT cell line (CD161hi) and between those seen for clones MC.7.G5 (CD161lo) and MC.27.759S (CD161medium) (Figure 3B).